Pharma / Biotech

New Support for Checkpoint Agents

Chicago—In the first-line treatment of non-small cell lung cancer (NSCLC), new studies suggest that biomarkers for checkpoint ligand PD-L1 expression and tumor mutational burden (TMB) will guide how they are used.

Source link




Related posts

CENP-E as a target for cancer therapy: Where are we now?

Newsemia

TACROLIMUS Capsule [Sandoz Inc]

Newsemia

AQUTOP MOISTURIZING SIGNATURE TONE-UP CREAM (Dimethicone) Cream [ALABLE CO., LTD.]

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy